Serveur d'exploration Tocilizumab - Exploration (Accueil)

Index « Teeft.i » - entrée « Pfizer »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Pfapa syndrome < Pfizer < Pfizer consumer healthcare  Facettes :

List of bibliographic references indexed by Pfizer

Number of relevant bibliographic references: 86.
[0-20] [0 - 20][0 - 50][20-40]
Ident.Authors (with country if any)Title
002918 (2013) C. Han ; A. Kavanaugh ; M. C. Genovese ; A. Deodhar [États-Unis] ; B. Hsu [États-Unis] ; E. Hsia [États-Unis]THU0513 Sustained Improvement in Health Related Quality of Life, Work Productivity, Employability, and Reduced Healthcare Resource Utilization of Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Treated with Golimumab:5yr Results
002919 (2013) B. Fautrel [France] ; J.-M. Joubert ; G. Cukierman ; C. Laurendeau ; J. Gourmelen [France] ; F. FagnaniTHU0512 Rheumatoid Arthritis (RA), Comorbidities and Biological Agents Uptake in France: Analysis of a National Claims Database
002920 (2013) B. C. M. Wang ; W. E. Furnback ; J. P. Ney [États-Unis] ; L. P. Garrison [États-Unis] ; C. Fang [République populaire de Chine]THU0511 Estimating the Burden of Illness of Fibromyalgia in Taiwan
002A00 (2013) K. Kume ; K. Amano ; S. Yamada ; T. Kanazawa ; H. Ohta ; K. Hatta [Japon]THU0211 Combination of Intra-Articular Steroid Injection and Etanercept More Effective Than Etanercept in Rapid Radiographic Progression Patients with Rheumatoid Arthritis: A Randomized, Open Label, X Ray Reader Blinded Study
002A01 (2013) K. Funahashi ; I. Kashiwagi ; S. Koizumi ; T. Matsubara [Japon]THU0210 Satisfaction of RA Patients Using Biologics Correlates with Changes in Disease Activity from the Start of Administration
002A02 (2013) J. S. Smolen [Autriche] ; A. Kavanaugh [États-Unis] ; D. Van Der Heijde [Pays-Bas] ; S. Florentinus [France] ; S. S. Rathmann [États-Unis] ; H. Kupper [Allemagne] ; E. C. Keystone [Canada]THU0209 Disease Activity and Structural Damage-Related Differences in Functional Disability in Early and Established Rheumatoid Arthritis
002A03 (2013) A.-F. F. Negoescu [Royaume-Uni] ; S. M. Abraham [Royaume-Uni]THU0175 Extra-Articular Manifestations of Rheumatoid Arthritis Develop in Patients Receiving Anti-TNF Treatment - A Retrospective Study
002A04 (2013) A. Balu [Royaume-Uni] ; S. Smith [Royaume-Uni] ; A. Yarwood [Royaume-Uni] ; K. Mcallister [Royaume-Uni] ; S. Eyre [Royaume-Uni] ; D. Plant [Royaume-Uni] ; K. Hyrich [Royaume-Uni] ; A. W. Morgan [Royaume-Uni] ; A. G. Wilson ; J. D. Isaacs [Royaume-Uni] ; A. Barton [Royaume-Uni]THU0174 Impact of IL-6R and IL-6ST Polymorphisms on Response to Anti-TNF Therapy in UK Patients – Results from the Braggss Cohort
002A05 (2013) A. Frazier-Mironer [France] ; A. Cantagrel [France] ; B. Combe [France] ; V. Deschamps ; M. Dougados [France] ; R.-M. Flipo ; I. Logeart ; X. Mariette ; T. Schaeverbeke ; J. Sibilia [France] ; X. Le Loët [France]THU0173 Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biologic Therapy in Patients with Rheumatoid Arthritis in Daily Practice: The Maintain Study
002A20 (2013) C. Gabay ; M. Riek [Suisse] ; A. Scherer [Suisse] ; A. FinckhTHU0135 Shorter Drug Retention in Rheumatoid Arthritis Patients Treated with Biological Dmards in Monotherapy – an Observational Cohort Analysis
002A21 (2013) C. Gaujoux-Viala [France] ; L. Gossec [France] ; M. Dougados [France] ; F. Guillemin [France] ; B. Fautrel [France]THU0134 Favorable Outcome, a New Concept for the Evaluation of Health Status in Rheumatoid Arthritis (RA) not so Easy to Achieve: Results from the Espoir Cohort
002B13 (2013) A. Koutsonikoli ; M. Trachana ; V. Tzimouli ; E. Farmaki ; N. Printza ; A. Garyfallos ; V. Galanopoulou [Grèce] ; P. Pratsidou-Gertsi ; F. Papachristou ; F. Kanakoudi-TsakalidouSAT0473 Novel Biomarkers for the Assessment of Pediatric Systemic Lupus Erythematosus Nephritis (Preliminary Report)
002B15 (2013) G. Almanzar [Allemagne] ; K. Sustal [Allemagne] ; R. Trippen [Allemagne] ; K. Höfner [Allemagne] ; M. Prelog [Allemagne]SAT0464 Disease Status Influences the Balance and Cytokine Profile in Patients with Juvenile Idiopathic Arthritis
002B16 (2013) G. Horneff ; S. Nimmrich [Allemagne]SAT0463 Incidence of Herpes Zoster Infections in Juvenile Idiopathic Arthritis Patients – Experience of the Biker Registry
002B17 (2013) G. Horneff ; N. Onken ; A. Hospach [Allemagne] ; G. Ganser ; H. I. Huppertz [Allemagne]SAT0462 Experience with Tocilizumab in 29 Patients with Systemic Onset Juvenile Idiopathic Arthritis
002B32 (2013) F. De Benedetti [Italie] ; N. Ruperto [Italie] ; G. Espada [Italie] ; V. Gerloni [Italie] ; B. Flato [Norvège] ; G. Horneff [Italie] ; B. Myones ; K. Onel ; J. Frane [États-Unis] ; J. Wang [Royaume-Uni] ; T. Lipman [États-Unis] ; K. Bharucha [États-Unis] ; A. Martini [Italie] ; D. LovellSAT0438 Catch-Up Growth During Tocilizumab Therapy for Systemic Juvenile Idiopathic Arthritis: 2-Year Data from a Phase 3 Clinical Trial
002B50 (2013) T. Kasama [Japon] ; M. Umemura [Japon] ; S. Isojima [Japon] ; T. Tokunaga [Japon] ; H. Tsukamoto [Japon] ; R. Yanai [Japon] ; H. Furuya [Japon] ; Y. Miwa [Japon]SAT0141 Correlation of Serum Macrophage Migration Inhibitory Factor Levels With Response to Tocilizumab Therapy in Patients with Rheumatoid Arthritis
002B51 (2013) T. Takeuchi [Japon] ; Y. Tanaka ; K. Amano ; J. Kikuchi [Japon] ; E. Tanaka [Japon] ; S. Hirata ; H. Nagasawa ; H. Yasuoka [Japon] ; H. Yamanaka [Japon]SAT0140 Effectiveness of Abatacept Against Rheumatoid Arthritis in Daily Clinical Practice - Orbit Study
002B52 (2013) T. Kojima [Japon] ; N. Takahashi [Japon] ; K. Funahashi [Japon] ; D. Kato [Japon] ; Y. Hattori [Japon] ; M. Hanabayashi [Japon] ; N. Asai [Japon] ; N. Ishiguro [Japon]SAT0139 Importance of Concomitant MTX Use During Treatment with Tocilizumab in Patients with Rheumatoid Arthritis
002B58 (2013) S. Saevarsdottir ; L. Stawiarz [Suède] ; C. Turesson [Suède] ; S. LinbladSAT0133 Previous Biological Therapies Influence Drug Survival in Rheumatoid Arthritis Patients Starting Abatacept Treatment 2006-2012.
002B59 (2013) R. F. Van Vollenhoven [Suède] ; P. Emery [Royaume-Uni] ; C. O. Bingham [États-Unis] ; E. Keystone [Canada] ; R. M. Fleischmann [États-Unis] ; D. Furst [États-Unis] ; E. W. Hessey [Royaume-Uni] ; A. Vashishtha [États-Unis] ; A. Mehbob [Royaume-Uni] ; P. B. Lehane [Royaume-Uni]SAT0131 Long-Term Safety of Rituximab: Pooled Analysis of the Rheumatoid Arthritis Global Clinical Trial Programme Over 11 Years

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Teeft.i -k "Pfizer" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Teeft.i  \
                -Sk "Pfizer" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    Teeft.i
   |clé=    Pfizer
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021